Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 87

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 87
---
 31,AmountsRemainder of 2025$1,877 20264,314 20276,999 20287,173 20296,858 Thereafter47,461 Total future minimum lease payments74,682 Less: amount representing interest34,229 Present value of future lease payments40,453 Less: short-term lease liabilities4,282 Long-term lease liabilities$36,171  The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period. The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Operating lease expense$1,912 $1,824 $6,274 $4,914 Cash paid for amounts included in the measurement of lease liabilities$1,722 $1,967 $5,620 $5,274 ContingenciesFrom time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Although the outcomes of such matters cannot be predicted with certainty, the Company believes there is no litigation pending that could have, either individually or in the aggregate, a material adverse impact on the Company's consolidated financial statements.On May 1, 2025, the Company filed a complaint in federal court in the Eastern District of Texas alleging that Sonic Healthcare USA, Inc., the healthcare company that is believed to offer ThyroSeq v3, is infringing three of the Company’s patents related to molecular testing of thyroid nodules. The complaint seeks treble damages, attorneys’ fees and costs as well as injunctive relief. On June 4, 2025, the Company filed an amended complaint asserting two additional patents. On July 21, 2025, Sonic Healthcare USA, Inc. filed an answer and a motion to dismiss. The Company filed its opposition to the motion to dismiss on October 31, 2025. The jury trial is currently scheduled for January 25, 2027.

18

7. Stockholders’ Equity

 Common Stock The Company had reserved shares of common stock for issuance as follows:  September 30, 2025December 31, 2024Stock options and restricted stock units issued and outstanding5,170,600 5,773,382 Stock options and restricted stock units available for grant under